PART I We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program. AXPAXLI is currently ...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-05 | 2025-12-31 | 0001104659-26-010664 | EDGAR | 129K words |
| 2025-03-03 | 2024-12-31 | 0001558370-25-002000 | EDGAR | — |
| 2024-03-11 | 2023-12-31 | 0001558370-24-002902 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0001558370-23-002908 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001558370-22-002363 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001558370-21-002813 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002537 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001558370-19-001659 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001558370-18-001678 | EDGAR | — |
| 2017-03-10 | 2016-12-31 | 0001558370-17-001627 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-105919 | EDGAR | 29K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010177 | EDGAR | — |
| 2025-05-05 | 2025-03-31 | 0001558370-25-006225 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015613 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001558370-24-011202 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007065 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017989 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001558370-23-013591 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001558370-23-008510 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001558370-22-016610 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012623 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001558370-22-007812 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-27 | 0001104659-26-021541 | EDGAR | 0K words |
| 2026-02-05 | 0001104659-26-010633 | EDGAR | — |
| 2026-01-23 | 0001104659-26-006015 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122564 | EDGAR | — |
| 2025-12-05 | 0001104659-25-118940 | EDGAR | — |
| 2025-11-04 | 0001104659-25-105914 | EDGAR | — |
| 2025-09-30 | 0001104659-25-094758 | EDGAR | — |
| 2025-09-30 | 0001104659-25-094724 | EDGAR | — |
| 2025-08-05 | 0001104659-25-073909 | EDGAR | — |
| 2025-06-11 | 0001104659-25-058525 | EDGAR | — |
236 total filings indexed. 204 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001393434 |
| Ticker | OCUL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ocutx.com |
| Listed | 2014-07-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report